Print version ISSN 0004-2730
Arq Bras Endocrinol Metab vol.55 no.6 São Paulo Aug. 2011
Bariatric surgery: an IDF statement for obese Type 2 diabetes*
Cirurgia bariátrica: uma comunicação da IDF sobre o diabetes tipo 2 em obesos
Dixon JBI; Zimmet PI; Alberti KGII; Rubino FIII; on behalf of the International Diabetes Federation Taskforce on Epidemiology and Prevention
IBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
IIImperial College London, London, UK
IIIWeill Cornell Medical College of Cornell University, New York, NY, USA
The International Diabetes Federation Taskforce on Epidemiology and Prevention of Diabetes convened a consensus working group of diabetologists, endocrinologists, surgeons and public health experts to review the appropriate role of surgery and other gastrointestinal interventions in the treatment and prevention of Type 2 diabetes. The specific goals were: to develop practical recommendations for clinicians on patient selection; to identify barriers to surgical access and suggest interventions for health policy changes that ensure equitable access to surgery when indicated; and to identify priorities for research. Bariatric surgery can significantly improve glycaemic control in severely obese patients with Type 2 diabetes. It is an effective, safe and cost-effective therapy for obese Type 2 diabetes. Surgery can be considered an appropriate treatment for people with Type 2 diabetes and obesity not achieving recommended treatment targets with medical therapies, especially in the presence of other major co-morbidities. The procedures must be performed within accepted guidelines and require appropriate multidisciplinary assessment for the procedure, comprehensive patient education and ongoing care, as well as safe and standardized surgical procedures. National guidelines for bariatric surgery need to be developed for people with Type 2 diabetes and a BMI of 35 kg/m2 or more.
A Força-Tarefa para Epidemiologia e Prevenção da International Diabetes Federation reuniu um grupo de trabalho com diabetologistas, endocrinologistas, cirurgiões e especialistas em saúde pública para revisar o papel correto da cirurgia e outras intervenções gastrointestinais no tratamento e prevenção do diabetes tipo 2 em obesos. Os objetivos específicos foram: desenvolver recomendações práticas para a seleção dos pacientes; identificar barreiras ao acesso à cirurgia e sugerir intervenções para mudanças das políticas de saúde que garantam equidade de acesso à cirurgia, quando indicada, e identificar prioridades para a pesquisa. A cirurgia bariátrica pode gerar uma melhora significativa no controle glicêmico em pacientes com obesidade grave e diabetes tipo 2. Ela é um tratamento efetivo, seguro e de bom custo-benefício para pacientes obesos com diabetes tipo 2. A cirurgia pode ser considerada um tratamento apropriado para pessoas com diabetes tipo 2 e obesidade que não consigam atingir as metas recomendadas de tratamento com terapias medicamentosas, especialmente na presença de outras comorbidades maiores. Os procedimentos devem ser executados por meio de diretrizes aceitas e requerem uma avaliação multidisciplinar, um processo amplo de educação do paciente e cuidados contínuos, além de procedimentos cirúrgicos seguros e padronizados. As diretrizes nacionais para a cirurgia bariátrica devem ser desenvolvidas para pacientes com diabetes tipo 2 e IMC de 35 kg/m2 ou mais.
The working group reviewed literature focusing on bariatric surgery published between 1991 and 2010, in the areas of national and international guidelines, systematic reviews of the literature and high-quality clinical trials for the treatment of obesity and diabetes in adults and adolescents. The group synthesized the available evidence for efficacy, safety and costeffectiveness of the established bariatric procedures in relation to current standard therapy for people with obesity and Type 2 diabetes. The group also explored weight loss and non-weight loss effects of the surgery on glycaemic control and novel gastrointestinal procedures and devices being developed to treat Type 2 diabetes. All papers identified were English-language, full-text papers.
Why is this position statement needed?
The global prevalence of Type 2 diabetes is rising dramatically, driven by an 'obesogenic' environment that favours increasing sedentary behaviour and easier access to attractive calorie-dense foods acting on susceptible genotypes (1). The most recent global predictions by the International Diabetes Federation (IDF) suggest that there are 285 million people with diabetes currently worldwide. This is set to escalate to 438 million by 2030 (2), with a further half billion at high risk. Diabetes is looming as one of the greatest public health threats of the 21st century.
Type 2 diabetes is a risk factor for vascular damage: both microvascular (retinopathy; nephropathy and neuropathy) and macrovascular (premature and more extensive cardio-, cerebro- and peripheral vascular disease). Premature mortality and morbidity in diabetes result from such complications. The disease results from inadequate insulin production and action and results in hyperglycaemia, but is also associated with multiple other dysfunctions involving lipid metabolism, oxidative stress, inflammation and haemato-rheology. In addition, obesity, by itself, generates similar cardio-metabolic dysfunction (3).
The dramatic rise in the prevalence of obesity and diabetes has become a major global public health issue (2). The problem is complex (4) and will require strategies at many levels to prevent, control and manage.
There is increasing evidence that the health of obese people with Type 2 diabetes, including the metabolic control of diabetes and its associated risk factors, can benefit substantially from bariatric surgery – that is, surgical procedures to produce substantial weight loss (5,6).
Several gastrointestinal (GI) operations that were originally designed to treat morbid obesity also cause dramatic improvement of Type 2 diabetes and can effectively prevent progression from impaired glucose tolerance to diabetes in severely obese individuals (7). In addition, bariatric surgery has been shown to substantially improve hypertension, dyslipidaemia and sleep apnoea (8) and several reports have documented an improvement of overall survival (5) and specific reduction in diabetes-related mortality (9).
Despite a number of evidence-based reviews and consensus statements having been published regarding the utilization of bariatric surgery in patients with obesity and diabetes (10-15), the IDF has not previously considered this rapidly developing area of care for worldwide use. Therefore, a need exists for worldwide expert guidance in the preoperative evaluation, choice of interventional procedure, perioperative management and long-term care of patients who seek surgery to improve diabetes control.
The IDF Taskforce on Epidemiology and Prevention convened a consensus working group of diabetologists, endocrinologists, surgeons and public health experts in December 2010 to discuss the appropriate role of bariatric surgery and other gastrointestinal interventions in the treatment and prevention of obesity and Type 2 diabetes. The specific goals of the panel were: to develop practical recommendations for clinicians; to identify barriers that currently prevent access to surgery and suggest interventions for health policy changes that ensure equitable access to surgery when indicated; and to identify priorities for clinical research.
This consensus statement considers primarily established bariatric surgical procedures. It is acknowledged that this is an emerging field and there is a large range of novel extraluminal and endoluminal gastrointestinal surgical procedures and devices that are in the development phase. Some focus primarily on weight loss and others additional non-weight loss metabolic benefits. The use of these requires further validation before they can be recommended.
How is obesity defined?
Obesity is usually classified by body mass index (BMI), calculated as body weight in kilograms divided by the height in metres squared (kg/m2). Classifications of BMI, as defined by the World Health Organization (WHO), based on associations with adverse health consequences, are listed in Table 1. Other methods, including waist circumference and central and peripheral fat mass, have also been used, but currently the clearest evidence suggests continued use of BMI as an index of obesity, particularly when BMI exceeds 30 kg/m2.
BMI categories have been developed primarily in populations of mainly European ethnicity, and often underestimate health risks in other populations. In addition, BMI does not necessarily reflect the proportion of body weight that consists of fat or the distribution of fat: both these aspects of body composition can affect the health risks of excess weight. Nevertheless, at present, in the absence of a better alternative, BMI is the internationally accepted standard used by researchers and policymakers to allocate individuals to different size categories.
Clinically severe or 'morbid' obesity is considered to be class III obesity or class II obesity with significant obesity-related co-morbidity, including Type 2 diabetes (Table 1). Additional cut-points for public health action have been suggested to address the increased risk of diabetes and cardiovascular disease in Asian populations and further investigation should examine other at-risk ethnicities.
The link between obesity and Type 2 diabetes
Type 2 diabetes is a heterogeneous disorder and, while its causes have yet to be fully explained, obesity is considered the primary risk factor (16). It has been estimated that the risk of developing Type 2 diabetes is increased 93-fold in women and 42-fold in men who are severely obese rather than of healthy weight (17,18).
A small proportion of people with Type 2 diabetes, approximately 15% in populations of European origin, are not overweight (19).
In the short term, even modest weight loss in people with Type 2 diabetes who are overweight or obese is associated with improvements in glycaemic control and associated conditions such as hypertension and dyslipidaemia (20). However, there is strong evidence that significant weight loss achieved by using lifestyle and medical methods by obese, particularly severely obese, people is modest and rarely sustained, particularly in the severely obese (5,21,22). There are now few medications approved for weight loss with recent withdrawals associated with adverse events.
Negative attitudes toward obesity
There are widely held community attitudes that the majority of obese individuals are responsible for their current weight. Severe obesity is too often misconstrued as a 'cosmetic' problem and a result of personal failure or lack of motivation.
However, this perspective ignores the very strong genetic and developmental bases to severe obesity (23) compounded by physical, emotional and societal issues. It also fails to consider the pervasive obesity-promoting effects of modern societies (the 'obesogenic environment') (24), where an abundant food supply, changes in food preparation, increasing sedentary behaviour and other lifestyle factors mitigate against weight control for individuals. Additionally, it ignores the emerging evidence that body weight is defended by powerful physiological mechanisms (25,26), making long-term maintenance of weight loss difficult.
In the context of treatment, negative societal attitudes have been a barrier to the provision of clinically effective, and costeffective, health care for people with severe obesity and Type 2 diabetes (27,28). As noted earlier, obesity is a complex, multifactorial and chronic disorder with serious adverse consequences for health, which requires a comprehensive approach to both prevention and treatment. People affected by severe obesity often struggle not only with the health and physical consequences of their chronic condition, but discrimination at work, socially and within the healthcare system.
Why consider bariatric surgery?
Both insulin resistance and insulin secretory reserve are important in the pathogenesis of Type 2 diabetes (29), but to different extents in different people. It is very important to recognize that not all Type 2 diabetes is the same and it is currently difficult to match the different therapies available to different phenotypes often resulting to suboptimal responses to therapy.
Type 2 diabetes is a progressive disease and the usual natural history is of progressive loss of insulin secretory capacity over time and the need for intensification of therapy and polypharmacy (30). Arresting this progression is a formidable therapeutic challenge. Treatment for Type 2 diabetes must also include active management of all cardiovascular risk factors (hypertension, dyslipidaemia, smoking and inactivity) but glycaemic control is very important – and not just for prevention of microvascular disease. Years of improved glycaemic control continue to deliver reduced risk of macrovascular disease and mortality over subsequent years (31,32).
Given the role of obesity in the aetiology of Type 2 diabetes, guidelines on its treatment provide that weight loss, with its many benefits, should be the most logical and cost-effective means of controlling Type 2 diabetes (16). Lifestyle interventions to promote weight loss and increase physical activity should be included as an essential component of diabetes treatment regimens.
Medical therapeutic options targeting primarily glucose control are all ideally added to, and not exchanged for, lifestyle change. Unfortunately, such strategies have very limited success in controlling blood glucose levels amongst the severely obese, with many of these patients not achieving targets. A number of these medications used for treating Type 2 diabetes, including insulin, themselves can result in weight gain.
A major problem for managing Type 2 diabetes is the need for continuous monitoring and intensification of therapies by adding new agents in increasing doses over time. The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus statement recommends that an HbA1c of 7% (53 mmol/mol) is a call to action (33). Some national guidelines, such as those from the UK's National Institute for Health and Clinical Excellence (NICE) (12), support more vigorous intensification of glycaemic therapies in the early stages of diabetes. NICE used HbA1c ³ 6.5% (48 mmol/mol) to increase from monotherapy, but ³ 7% (53 mmol/mol) for increasing to triple therapies and beyond. This is very important. In one trial that randomized people with Type 2 diabetes and existing cardiovascular disease to very intensive management targeting HbA1c < 6.5% (48 mmol/mol), mortality was higher in the intensive group, driven by deaths in those people who failed to show HbA1c improvement as treatment was intensified (31). This should not be taken to mean people with early Type 2 diabetes should be treated less vigorously as the legacy effect of early intervention is considerable (34).
A critical issue has been the rate at which healthcare professionals escalate therapies. Current approaches that rely on loss of glycaemic control and on intensifying lifestyle or other time-consuming measures set clinicians up for failure to achieve targets (35).
It may be possible to achieve much more in terms of complication prevention – or even possibly slowed rate of progression – if treatments are started and intensified early. There have even been suggestions of starting polypharmacy at diagnosis (36,37), but there is limited current evidence to demonstrate the efficacy of this (31).
Apart from the side-effect profiles and suboptimal deployment of existing medical diabetes therapies, there remain issues around patient engagement in many aspects of their lives. Very few clinical services routinely provide psychological support to encourage lifelong engagement in self-care.
The continuing morbidity and mortality in persons with diabetes is a sign that the answer as to the best management for Type 2 diabetes in terms of maximizing metabolic control is still elusive. Given this scenario, the option of bariatric intervention needs to be considered in appropriately selected individuals.
Evolving concept: bariatric-metabolic surgery
The term 'bariatric' surgery, derived from the Greek word baros for weight, defines surgical procedures designed to produce substantial weight loss. Accordingly, goals of bariatric surgery originally evolved around achieving substantial sustained weight loss. In reality, weight loss is only one of the outcomes of such surgery. Bariatric surgery can be associated with substantial other health benefits, including improvement or normalization of hyperglycaemia. hyperlipidaemia, blood pressure, obstructive sleep apnoea and improved quality of life (38).
In view of the broad benefits of weight loss and the growing evidence that some bariatric procedures provide metabolic changes that cannot be explained completely by their effects on body weight alone (39), thename 'bariatric-metabolic surgery' is emerging as a more appropriate name.
Bariatric surgery and Type 2 diabetes
Bariatric procedures aim to reduce weight and maintain weight loss through altering energy balance, primarily by reducing food intake and modifying the physiological changes that drive weight regain. There also appear to be independent metabolic benefits, associated with effects of incretins and possibly other hormonal or neural changes after some surgical procedures (40), in addition to weight loss. For example, rapid and sustained improvements in glycaemic control can be achieved within days of gastric bypass surgery, before any significant weight loss is evident (41,42).
A 2009 Cochrane review including patients with and without diabetes concluded that bariatric surgery resulted in greater weight loss than conventional treatment in obese class I (BMI > 30 kg/m2) as well as severe obesity, accompanied by improvements in co-morbidities such as Type 2 diabetes, hypertension and improvements in health-related quality of life (38).
A less rigorous systematic review and meta-analysis of 621 studies which included approximately 135,000 patients identified 103 studies reporting on the remission of the clinical and/or laboratory manifestations of diabetes (6). Overall, 78.1% of patients had 'remission' of diabetes following surgery. Among patients with diabetes at baseline, 62% remained in remission more than 2 years after surgery. There were significant limitations to this review as remission was largely based on clinical reporting, not HbA1c or other biochemical outcomes, and follow-up of most cohorts poorly described.
The Swedish Obese Subjects study clearly demonstrated the prevention and sustained remission of Type 2 diabetes in a group of 2037 (7) severely obese patients electing to have bariatric surgery when compared with well-matched controls at 2 and 10 years follow-up (Table 2).
The extent of remission of Type 2 diabetes is influenced by the extent of weight loss, weight regain, duration of diabetes, the pre-surgery hypoglycaemic therapy requirements, and the choice of bariatric procedure. In addition, each patient's commitment to modifying their diet and levels of exercise within a framework of ongoing multidisciplinary care will influence outcomes.
Remarkably, there is only a sole acceptably designed prospective randomized control trial (RCT) which has investigated bariatric surgery specifically as a treatment for Type 2 diabetes (43). It compared laparoscopic adjustable gastric banding as part of a comprehensive management programme to conventional diabetes therapy with a focus on weight loss by diet and exercise. After 2 years, remission of diabetes was significantly more common in those who had received surgery (73 vs. 13%).
Bariatric surgery benefits beyond diabetes?
Severe obesity is associated with a large number of health problems in addition to Type 2 diabetes. A review of more than 1.4 million participants in prospective studies largely from North America, Europe and Australia show a consistent progressive rise in the mortality hazard ratios with increasing BMI (44) (Table 3). A similar analysis by the Prospective Studies Collaboration found the risk of diabetes-related death was quadrupled for morbidly obese individuals (45).
Follow-up of participants in the Swedish Obese Subjects Study after an average of 11 years found that bariatric surgery was associated with a 29% reduction in all-cause mortality after accounting for sex, age and risk factors in this severely obese group (5). Bariatric surgery also led to a specific reduction in cancer incidence in women (46). Other studies have confirmed this mortality advantage when compared with community matched control subjects (9,47). A large retrospective cohort study of almost 8,000 patients who had undergone gastric bypass surgery were compared for long-term mortality with age-, sex- and BMI-matched control subjects who had applied for driver's licences (Utah, USA) (9). The analysis reported an adjusted long-term all-cause mortality reduction of 40% in the surgical group. Specific mortality reductions in the operated group were 56% for coronary artery disease, 92% for diabetes and 60% for cancer when compared with matched controls.
It would be expected that morbidly obese patients who have bariatric surgery as a treatment primarily for Type 2 diabetes would also experience the benefits of weight loss on other aspects of their health; for example, debilitating osteoarthritis or obstructive sleep apnoea. Many studies have demonstrated major improvements in health-related quality of life following bariatric surgery using both generic and obesity-specific quality-of- life instruments (48,49).
Is bariatric surgery cost-effective?
The costs of Type 2 diabetes are substantial. In the USA, the lifetime cost has been estimated at $US 172,000 for a person diagnosed at the age of 50 years and $US 305,000 if diagnosed at the age of 30 years (50). The estimate included both the direct medical costs of diabetes and its complications and indirect costs caused by work absence, reduced productivity at work, disability and premature death. Over 60% of the medical cost was incurred within 10 years of diagnosis. Bariatric surgery for severe obesity, regardless of diabetes status, has been assessed as cost-effective (51) and, in some analyses, cost saving or dominant (52).
A literature review identified three cost-effective analyses of bariatric surgery for patients specifically with diabetes (Table 4). All three studies found bariatric surgery to be either very cost-effective or dominant as a therapy for Type 2 diabetes relative to standard therapy. Study analyses have been conservative. The finding of 'cost-effectiveness' indicates that health benefits are achieved at an acceptable price relative to country-specific cost-effectiveness thresholds. The 'dominant' result indicates that an intervention generates both cost savings and health benefits over the lifetime of the cohort. This is a rare outcome and provides the most compelling evidence for funding based on economic criteria.
It is recognized that cost-effectiveness studies have not been conducted in low- and middle-income countries where high cost interventions for macro- and microvascular complications may not be available. However, life expectancy might indeed be improved by bariatric surgery in these settings and morbidity decreased. It is up to each health system to determine whether bariatric surgery with its support services is economically appropriate when weighed against the provision of essential medicines and other secondary prevention initiatives, such as foot care, education and retinal screening, which can be cost saving in low-income countries.
What eligibility guidelines exist?
A number of guidelines exist on the use of bariatric surgery for the treatment of severe obesity in general, and for the treatment of Type 2 diabetes in particular. They are summarized in Table 5. Most of the existing guidelines reflect the expert recommendations of the National Institutes of Health (NIH) Consensus Development Conference Statement March 1991. The current NIH website warns that their information is dated and provided solely for historic purposes (53).
A recent Diabetes Surgery Summit of 50 international experts examined gastrointestinal surgery for the management of Type 2 diabetes. Delegates strongly endorsed that conventional gastrointestinal surgery – Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable gastric band (LAGB) or bilio-pancreatic diversion (BPD) – should be considered for the treatment of Type 2 diabetes in acceptable surgical candidates with BMI > 35 kg/m2 who are inadequately controlled by lifestyle and medical therapy. Further trial evidence was deemed necessary for inadequately controlled Type 2 diabetes in candidates suitable for surgery with mild-to-moderate obesity (BMI 30.35 kg/m2) (14).
Recommendations for adolescents
Long-term whole-of-family lifestyle change, with high-quality medical management, is the mainstay of paediatric obesity treatment. However, the growing prevalence of severe obesity in children and adolescents demonstrates a need for additional therapy. Bariatric surgery is only considered suitable for adolescents of developmental and physical maturity. There are a range of guidelines and consensus reports that have similar recommendations.
A recent position statement was developed by the Australian and New Zealand Colleges for paediatric physicians and surgeons and the Obesity Surgery Society of Australia and New Zealand (54). The statement recommended surgery be considered if adolescents had BMI > 40 kg/m2, or > 35 kg/m2 with severe co-morbidities (including Type 2 diabetes), were aged 15 years or more, with Tanner pubertal stage 4 or 5 and skeletal maturity, and could provide informed consent. Potential candidates should have failed a multidisciplinary programme of lifestyle ± pharmacotherapy for 6 months, and they and their family must be motivated and understand the need to participate in post-surgical therapy and follow-up. Surgery should be provided in units affiliated with teams experienced in the assessment and long-term follow-up of the metabolic and psychosocial needs of adolescent patients. Very similar eligibility criteria, with some variation in youngest age and BMI, have been listed in European and US publications (10,55).
This IDF position statement advises that only two procedures, namely Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB), are currently conventional bariatric surgical procedures for adolescents.
Do procedures vary in effectiveness?
A number of bariatric surgical procedures are effective in achieving weight loss. Those that involve more extensive surgery, such as Roux-en-Y gastric bypass, generally lead to greater weight loss and more profound metabolic changes, at least initially, than less invasive, non-diversionary procedures such as laparoscopic adjustable gastric banding. Roux-en-Y gastric bypass procedures influence the gut hormonal milieu and provide an early non-weight related improvement in glycaemic control of Type 2 diabetes. It is not clear if these changes are durable or have a fundamental effect on the underlying mechanisms driving Type 2 diabetes. In the longer term, weight loss may be the key benefit. There is absolutely no evidence to support subcutaneous lipectomy (liposuction) as a treatment for Type 2 diabetes in obese patients (56).
A systematic review of the literature by Buchwald and cols. (6) reported that diabetes remits or improves in the majority of patients after bariatric surgery. The procedures producing greater excess weight loss lead to higher remission rates (Table 6). This review, however, was limited by the quality of the available literature where follow-up varied, there was no consistent definition of remission, and biochemical measures of remission were usually not reported.
The choice of bariatric procedure is complex, requiring a careful risk-benefit analysis and acceptance of variation in regional practice and expertise. The decision must be made by severely obese patients in consultation with their bariatric surgical multidisciplinary team.
It is important to recognize that all conventional surgical procedures vary in their risks and benefits and, to date, there are few hard data that can be used to mat-ch patients to procedures. Recommendations made by this consensus apply to currently accepted bariatric surgical procedures and do not apply to new experimental procedures or devices.
The consensus group consider that Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, bilio-pancreatic diversion (BPD) and the duodenal switch variant (BPD-SD), and sleeve gastrectomy (SG) as currently accepted procedures (57). However, it was acknowledged that there was limited medium- or long-term data regarding sleeve gastrectomy, and there are safety, nutritional and metabolic concerns with bilio-pancreatic diversion and the duodenal switch variant. Two procedures were considered accepted procedures in adolescents. Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding (see Recommendations for adolescents above).
What are the risks of bariatric surgery?
The 30-day mortality associated with bariatric surgery is estimated at 0.1%-0.3%, a rate similar to that for laparoscopic cholecystectomy (58) and described as 'low' (59). Programme and patient factors found to be associated with increased risk are shown in Table 7. The presence of Type 2 diabetes has not been found to be associated with increased risk for bariatric surgery.
The most common complications of bariatric surgery include anastomotic and staple-line leaks (3.1%), wound infections (2.3%), pulmonary events (2.2%) and haemorrhage (1.7%). Morbidity rates are lower after laparoscopic procedures, which constitute a steadily increasing proportion of bariatric operations (60).
A new study by the US Agency for Healthcare Research and Quality reported a 21% decline in complications after bariatric surgery between 2002 and 2006 (61). This work compared complications among > 9,500 patients who underwent obesity surgery at 652 hospitals in 2001-2002 vs. 2005-2006. Complication rates fell from ~24 to 15%, despite increases in the percentage of older and sicker operative patients. Postsurgical infection rates dropped by 58%, while other complications such as abdominal hernias, staple leakage, respiratory failure and pneumonia diminished by 29.50%. Other complications remained unchanged (ulcers, dumping, haemorrhage, wound re-opening, deep-venous thrombosis and pulmonary embolism, heart attacks and strokes) and none increased.
Early post-operative morbidity and mortality are related to the complexity of the surgery. The US Bariatric Outcomes Longitudinal Database (BOLD) reviewed over 57,000 consecutive procedures and reported one or more complication at 1-year rates of 4.6, 10.8, 14.9 and 25.7% following laparoscopic adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass and bilio-pancreatic diversion, respectively (62). Thirty-day post-surgical mortality follows a similar trend, with 0.1% for laparoscopic adjustable gastric band, 0.5% for Roux-en-Y gastric bypass and 1.1 for biliopancreatic diversion (58). The US Agency for Healthcare Research and Quality reported a ninefold increase in bariatric surgery for the period 1998-2004, with a reduction in overall early mortality from 0.89 to 0.19%. Improvements have been attributed to higher hospital volumes, a move to laparoscopic surgery and an increase in banding procedures (61).
Longer-term surgical complications and need for surgical revisions are not uncommon and expected problems are usually specific to the surgical intervention.
Early detection and appropriate management of complications is very important. All those managing post-bariatric surgical patients should have a low threshold for surgical referral should a complication be suspected. Longer-term concerns, especially with Roux-en-Y gastric bypass and bilio-pancreatic diversion, include vitamin and mineral deficiencies, osteoporosis and, rarely, Wernicke's encephalopathy and severe hypoglycaemia from insulin hypersecretion (11,63). Clinical guidelines developed by the American Association of Clinical Endocrinologists, The Obesity Society and the American Society for Metabolic and Bariatric Surgery address these important issues (11). A summary of nutritional risk with each procedure is shown in Table 8. Long-term dietary advice, evaluation and supplementation are required for all procedures.
The risks of each procedure need to be considered in the light of potential reductions in mortality, morbidity or co-morbidity, quality of life and productivity. Realistic expectations are important and the risk-benefit ratio assessed individually for each patient, accounting for both peri-operative risk and possible long-term complications (59).
Continuing efforts are required to monitor the safety, efficacy and long-term effects of bariatric surgery. There is a range of national bariatric surgery registries and continuing long-term longitudinal studies. We encourage the expansion of national registries and acknowledge that these must be well resourced to function appropriately. Severe obesity and Type 2 diabetes are chronic conditions needing a chronic-disease approach to care.
Components of successful bariatric surgery
There is a range of comprehensive guidelines for the use of bariatric procedures for obesity, including the UK National Institute for Health and Clinical Excellence (2006) (12), the combined American Association of Clinical Endocrinologists, The Obesity Society and the American Society for Metabolic and Bariatric Surgery guidelines (2008) (11) and European clinical guidelines (2007) (10).
Diabetes – Who to consider for surgery?
There is clear evidence that bariatric surgery is a very effective therapy for obese patients with Type 2 diabetes. The place of surgery in diabetes treatment algorithms needs to be established (see below). Currently, surgery is considered optional and, as such, in the countries with the highest bariatric surgery uptake, less than 2% of eligible patients are treated annually.
Indications for bariatric surgery typically classify those who are eligible for surgery, but a recommendation of surgical referral as best practice or prioritization has not been widely considered. Diabetes management algorithms should now include points at which bariatric surgery should be considered and points at which referral is recommended or prioritized (Table 9).
In patients with Type 2 diabetes, eligibility or prioritization for surgery should consider BMI, ethnicity, associated weight related co-morbidity, weight trajectory and the response of diabetes and co-morbidity to optimal medical therapy. Conditional eligibility or prioritization should be assessed by a team specializing in diabetes. Surgical referral implies a thorough bariatric surgical multidisciplinary team assessment of risk and benefit.
Contraindications for bariatric surgery include: current drug or alcohol abuse; uncontrolled psychiatric illness; and lack of comprehension of the risks-benefits, expected outcomes, alternatives and lifestyle changes required with bariatric surgery (11). In addition, there are general conditions that would contraindicate elective surgery and specific conditions that substantially increase the risk of surgery, later complications or poor outcomes. These should be assessed by the surgical team.
Integration into diabetes treatment algorithms
Existing international treatment guidelines for Type 2 diabetes provide little information or direction on the role of bariatric interventions in treatment. By contrast, the American Diabetes Association recommends that bariatric surgery be considered as a treatment option for Type 2 diabetes when the patient's BMI exceeds 35 kg/m2 (63). Algorithms developed for treating Type 2 diabetes should include recommendations as to where bariatric surgery is an option and the circumstances where it should be prioritized.
Almost all severely obese patients are unsuccessful in their efforts to achieve sustained and significant weight loss and there is evidence that weight loss induced by bariatric surgery can lead to remission of hyperglycaemia in the majority of patients with diabetes (6,64). Earlier intervention increases the likelihood of remission (65,66). In the remaining patients, residual hyperglycaemia is easier to manage following bariatric surgery. It can therefore be argued that bariatric surgery for the severely obese with Type 2 diabetes should be considered early as an option for eligible patients, rather than being held back as a last resort.
Equity of access to bariatric surgery
Obesity is more common in socio-economically disadvantaged people in the developed world, but the vast majority of bariatric surgery procedures in the developed world are performed in the private sector. Current access to surgical treatment for people with severe obesity and Type 2 diabetes is not equitable and discriminates against individuals who are most likely to benefit. There are particular problems in those emerging countries where rates of severe obesity are increasing rapidly and healthcare resources are extremely limited.
There will be resource implications in the short term from increasing access to bariatric surgery, but it is essential to consider not just the financial costs of the procedures and necessary follow-up, but also the potential savings from achieving improved control of Type 2 diabetes, its related metabolic and other complications and co-morbidities.
Measuring diabetes-related outcomes
There needs to be an agreed definition of success and, on the basis of present data, the achievable goal of bariatric surgery is not cure, but remission, of the diabetes state. Improved patient health would be recognized by individualized optimization of the metabolic state, which involves normalization or improvement of the metabolic state (Text box 5).
The above definitions, with a focus on diabetes, complement broader success measures, including substantial sustained weight loss, improved quality of life and improvement or remission of obesity-associated co-morbidity.
Type 2 diabetes: novel procedures and devices
Novel bariatric-metabolic procedures
Several novel procedures have developed from elegant experiments using rodent models to examine the mechanism of action of bariatric surgery. The aim has been to enhance the nonweight-loss glycaemic control benefits of the gastrointestinal interventions. These procedures may evolve as therapy for Type 2 diabetes in those without significant weight issues. These novel procedures include duodenal-jejunal bypass (DJB) (67) and ileal interposition (IT) (68).
First described by Rubino (69), duodenal-jejunal bypass is a stomach-sparing bypass of a short portion of proximal intestine, comparable with the segment excluded in a standard Roux-en-Y gastric bypass. A number of early human clinical trials have been performed and improvements in glycaemic control have been reported, but these may be less impressive in subjects with a lower BMI (70,71).
Ileal interposition involves the surgical transposition of a small segment of ileum into the proximal intestine. Generally, shortterm studies in humans have reported improved glycaemia (72,73).
These procedures remain experimental and are likely to require technical refinements before larger-scale longer-term safety and efficacy studies.
Novel bariatric-metabolic devices
Multiple, mostly novel, devices and techniques are being explored to utilize the gatrointestinal tract's putative mechanism for altering energy balance and for non-weight-loss effects on glucose tolerance. In general, the techniques can be divided by mode of placement into those that are upper gastrointestinal endoscopic or laparoscopic, with some combining approaches.
Endoscopically placed upper gastrointestinal devices include the simple positioning of a device in the upper gastrointestinal tract. Examples include intra-gastric balloons, which are currently available for temporary placement (usually 6 months, but repeat treatment for extending the duration of treatment beyond 2 years have been reported) and which provide 10%-15% weight loss during the period of placement, plus a range of novel devices under development, which are placed in the stomach to mimic restriction, or placed in the trans-pyloric area to delay or regulate gastric emptying. Some endoscopically placed devices are physically fixed to the upper gastrointestinal tract to mimic proximal gastric restriction of the laparoscopic adjustable gastric band, while some use endoluminal impervious sleeves to bypass the gastro-duodenal upper jejunal area to mimic the Roux-en-Y gastric bypass, or bypass the duodenum and proximal jejunum to mimic the duodenal-jejunal bypass.
A range of laparoscopic procedures to place novel electronic gastric or gastro-duodenal motility stimulators, and vagal nerveblocking devices are also under investigation. Results in humans to date have been mixed, with some devices providing inadequate weight loss and others promising results. These are considered less invasive than most conventional bariatric surgical procedures.
Whilst there is excitement in the novel medical device area, the efficacy, safety, durability and clinical utility of many of these procedures in the management of obese people with Type 2 diabetes is still to be established.
Clinically severe obesity is a complex and chronic medical condition. Bariatric surgery is an effective and cost-effective therapy for Type 2 diabetes and obesity with an acceptable safety profile. Surgery provides an appropriate treatment for people with Type 2 diabetes and obesity not achieving recommended treatment targets with medical therapies, especially when there are other major co-morbidities. National guidelines for bariatric surgery need to be developed and implemented for people with Type 2 diabetes. Bariatric surgery should be incorporated into Type 2 diabetes treatment algorithms and the establishment of national bariatric surgical registries recommended.
Conflict of interest: JD is a consultant for: Allergan Inc, manufacturer of the LapBand System®; Metagenics, manufacturer of Bariatric Advantage® nutritional supplements; and Scientific Intake, manufacturer of the SMART® device. He has received speakers' fees from Eli Lilly, the manufacturer of Byetta®; Nestle Australia, manufacturer of Optifast; Roche Products, manufacturer of Xenical; Weight Watchers; and Merck Sharp & Dohme. His institutions, Monash University and Baker IDI Heart & Diabetes Institute, have received support for his research from Allergan Inc, Nestle Australia and ResMed, manufacturer of C-PAP machines. He has received fees for the development of educational materials from Abbott Australasia and Novartis Pharmaceuticals Australia and as a co-director of educational programs for Florida Hospital, Miami Florida USA (Gastric Banding Summit); National Children's Hospital, Columbus Ohio USA (Chronic Diseases in Childhood Obesity: Risks and benefits of early intervention); and Quadrant Healthcom (Cleveland Clinic's MISS meeting, Morbid Obesity Track).
PZ has received a consulting fee from Covidien Australia.
GA has nothing to declare.
FR has received research grants from Roche and Covidien and serves on the Scientific Advisory Board of NGB Biotech. He also has received an educational grant from Covidien.
Acknowledgments: We acknowledge the contributions of Catherine Keating (Deakin University, Melbourne, Australia) for reviewing the cost-effectiveness of bariatric surgery and Gary Wittert (University of Adelaide, Australia) and Joe Proietto (University of Melbourne, Australia) for their constructive review of this Position Statement. We also acknowledge the assistance and direction provided by a group of Australian endocrinologists chaired by Professor Paul Zimmet (15). The consensus meeting was supported with an unrestricted educational grant by: Allergan Inc, Irvine, CA, USA; Ethicon, Ethicon Endo-Surgery Inc., Cincinnati, OH, USA; MetaCure Inc., Mount Laurel, NJ, USA. These companies played no role in the discussion or preparation of this position paper.
The IDF consensus meeting was held at the IDF head office in Brussels, Belgium (5-6 December 2010). This meeting was convened by:
Professor George Alberti
Imperial College, London and Newcastle University, UK
Professor John B. Dixon
Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
Professor Francesco Rubino Weill
Cornell Medical College, New York, NY, USA
Professor Paul Zimmet
Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
Other attendees at the meeting were:
Professor Stephanie Amiel
King's College, London, UK
Professor Louise A. Baur
University of Sydney, Australia
Professor Nam H. Cho
Ajou University School of Medicine, Korea
Dr. Bruno Geloneze Univerity of Campinas (UNICAMP), Brazil
Professor Jan Willem Greve
Atrium Medical Center, Parkstad Heerlen, the Netherlands
Professor Linong Ji
Peking Unviersity People's Hospital, China
Dr. Muffazal Lakdawala
Saifee Hospital, Mumbai, India
Professor Wei-Jei Lee
Ming-Sheng General Hospital, National Taiwan University, Taipei, Taiwan
Professor Pierre Lefebvre
International Diabetes Federation and University of Liege, Belgium
Dr. Carel le Roux
Imperial College London, UK
Professor Jean-Claude Mbanya International Diabetes Federation, Younde, Cameroon
Professor Gertrude Mingrone
Catholic University of Rome, Italy
Professor Philip R. Schauer Cleveland Clinic Lerner College of Medicine, USA
Professor Luc Van Gaal
Antwerp University Hospital, Belgium
Dr. David Whiting International Diabetes Federation, Brussels, Belgium
Professor Bruce M. Wolfe Oregon Health and Science University (OHSU), USA
All panel members made a substantial contribution to the meeting and subsequent formulation of the position statement
1. Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res ClinPract. 2010;87:2-3. [ Links ]
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res ClinPract. 2010;87:4-14. [ Links ]
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-80. [ Links ]
4. Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, Fortmann SP, et al. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the Expert Panel on Population and Prevention Science). Circulation. 2008;118:428-64. [ Links ]
5. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-52. [ Links ]
6. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122:248-56. [ Links ]
7. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.NEngl JMed. 2004;351:2683-93. [ Links ]
8. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and metaanalysis. J Am Med Assoc. 2004;292:1724-37. [ Links ]
9. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-61. [ Links ]
10. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes (Lond). 2007;31:569-77. [ Links ]
11. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Guven S, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. EndocrPract. 2008;14:S1-S83. [ Links ]
12. NICE. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. London: National Institute for Health and Clinical Excellence, 2006. [ Links ]
13. Lakdawala M, Bhasker A. Report: Asian Consensus Meeting on Metabolic Surgery. Recommendations for the use of Bariatric and Gastrointestinal Metabolic Surgery for Treatment of Obesity and Type II Diabetes Mellitus in the Asian Population: 9-10 August 2008, Trivandrum, India. Obes Surg. 2010;20:929-36. [ Links ]
14. Rubino F, Kaplan LM, Schauer PR, Cummings DE. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399-405. [ Links ]
15. Zimmet P, Campbell LV, Toomath R, Twigg S, Wittert G, Proietto J. Bariatric surgery to treat severely obese patientswith type 2 diabetes: a consensus statement. Obes Res ClinPract. 2011; (in press). [ Links ]
16. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30. [ Links ]
17. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-6. [ Links ]
18. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-9. [ Links ]
19. Gregg EW, Cheng YJ, Narayan KM, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976-2004. Prev Med. 2007;45:348-52. [ Links ]
20. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374-83. [ Links ]
21. Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;CD004095. [ Links ]
22. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;CD004096. [ Links ]
23. Farooqi IS, O'Rahilly S. Genetic factors in human obesity. Obes Rev. 2007;8:S37-40. [ Links ]
24. Swinburn B, Egger G. Prevention of type 2 diabetes. Prevention needs to reduce obesogenic environments. Br Med J. 2001;323:997. [ Links ]
25. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science. 2005;307:375-9. [ Links ]
26. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621-8. [ Links ]
27. Foo J, Toomath R, Wickremesekera SK, Bann S, Stubbs R. Bariatric surgery: a dilemma for the health system? N Z Med J. 2010;123:12-4. [ Links ]
28. Dixon JB. Referral for a bariatric surgical consultation: it is time to set a standard of care. Obes Surg. 2009;19:641-4. [ Links ]
29. Tripathy D, Chavez AO. Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. CurrDiab Rep. 2010;10:184-91. [ Links ]
30. UKPDS. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group, study 16. Diabetes. 1995;44:1249-58. [ Links ]
31. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983-90. [ Links ]
32. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Longterm follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-76. [ Links ]
33. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203. [ Links ]
34. Trompet S, de Craen AJ, Mooijaart S, Stott DJ, Ford I, Sattar N, et al. High innate production capacity of proinflammatory cytokines increases risk for death from cancer: results of the PROSPER Study. Clin Cancer Res. 2009;15:7744-8. [ Links ]
35. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002;45:S23-8. [ Links ]
36. Roman G, Hancu N. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. HormMetab Res 2009;41:116-22. [ Links ]
37. Bailey CJ, Del Prato S, Eddy D, Zinman B. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J ClinPract. 2005;59:1309-16. [ Links ]
38. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev. 2009;CD003641. [ Links ]
39. Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg. 2001;25:527-31. [ Links ]
40. Rubino F, R'Bibo SL, del Genio F, Mazumdar M, McGraw TE. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol.2010;6:102-9. [ Links ]
41. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J ClinEndocrinolMetab. 2008;93:2479-85. [ Links ]
42. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-50. [ Links ]
43. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. J Am Med Assoc. 2008;299:316-23. [ Links ]
44. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-9. [ Links ]
45. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-96. [ Links ]
46. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653-62. [ Links ]
47. Peeters A, O'Brien PE, Laurie C, Anderson M, Wolfe R, Flum D, et al. Substantial intentional weight loss and mortality in the severely obese. Ann Surg. 2007;246:1028-33. [ Links ]
48. Kolotkin RL, Crosby RD, Gress RE, Hunt SC, Adams TD. Two-year changes in health-related quality of life in gastric bypass patients compared with severely obese controls. SurgObesRelat Dis. 2009;5:250-6. [ Links ]
49. Dixon JB, Dixon ME, O'Brien PE. Quality of life after lap-band placement: influence of time, weight loss, and comorbidities. Obes Res. 2001;9:713-21. [ Links ]
50. Zhuo X, Zhang P, Hoerger T. Lifetime cost of type 2 diabetes in the US. Presented at the American Diabetes Association meeting, 25-29 June 2010, Orlando, FL, USA. Abstract 0434-PP. [ Links ]
51. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1-190, 215-357, iii-iv. [ Links ]
52. Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M. A study on the economic impact of bariatric surgery. Am J Manag Care. 2008;14:589-96. [ Links ]
53. National Institutes of Health (NIH). Website. Vol. 2010. Available at http://consensus.nih.gov/1991/1991gisurgeryobesity084html.htm Last accessed 18 December 2010. [ Links ]
54. Baur LA, Fitzgerald DA. Recommendations for bariatric surgery in adolescents in Australia and New Zealand. J Paediatr Child Health. 2010;46:704-7. [ Links ]
55. Inge TH, Krebs NF, Garcia VF, Skelton JA, Guice KS, Strauss RS, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics. 2004;114:217-23. [ Links ]
56. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-57. [ Links ]
57. Buchwald H, Oien DM. Metabolic⁄bariatric surgery worldwide 2008. Obes Surg. 2009;19:1605-11. [ Links ]
58. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621-32. [ Links ]
59. NHMRC. Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults. Canberra: National Health and Medical Research Council; 2003. [ Links ]
60. Nguyen NT, Hinojosa M, Fayad C, Varela E, Wilson SE. Use and outcomes of laparoscopic versus open gastric bypass at academic medical centers. J Am Coll Surg. 2007;205:248-55. [ Links ]
61. Encinosa WE, Bernard DM, Du D, Steiner CA. Recent improvements in bariatric surgery outcomes. Med Care. 2009;47:531-5. [ Links ]
62. DeMaria EJ, Pate V, Warthen M, Winegar DA. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. SurgObesRelat Dis. 2010;6:347-55. [ Links ]
63. ADA. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33:S11-61. [ Links ]
64. Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009;150:94-103. [ Links ]
65. Dixon JB, O'Brien P. Health outcomes of severely obese Type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care. 2002;25:358-63. [ Links ]
66. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-84. [ Links ]
67. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11. [ Links ]
68. Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J PhysiolEndocrinolMetab. 2005;288:E447–53. [ Links ]
69. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-9. [ Links ]
70. Geloneze B, Geloneze SR, Fiori C, Stabe C, Tambascia MA, Chaim EA, et al. Surgery for non-obese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg. 2009;19:1077-83. [ Links ]
71. Lee HC, Kim MK, Kwon HS, Kim E, Song KH. Early changes in incretin secretion after laparoscopic duodenal-jejunal bypass surgery in type 2 diabetic patients. Obes Surg. 2010;20:1530-5. [ Links ]
72. DePaula AL, Stival A, Halpern A, Vencio S. Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI < 35: an analysis of 454 consecutive patients. World J Surg. 2011;35:102-8. [ Links ]
73. Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P, et al. Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes TechnolTher. 2009;11:785-9. [ Links ]
74. WHO. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-63. [ Links ]
75. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253. [ Links ]
76. Keating CL, Dixon JB, Moodie ML, Peeters A, Bulfone L, Maglianno DJ, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care. 2009;32:567-74. [ Links ]
77. Hoerger TJ, Zhang P, Segel JE, Kahn HS, Barker LE, Couper S. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care. 2010;33:1933-9. [ Links ]
78. National Institutes of Health. Gastrointestinal surgery for severe obesity: NIH Consensus Development Conference Statement. Am J ClinNutr. 1992;55:615S-9S. [ Links ]
79. Logue J, Thompson L, Romanes F, Wilson DC, Thompson J, Sattar N. Management of obesity: summary of SIGN guideline. Br Med J. 2010;340:c154. [ Links ]
80. DeMaria EJ, Portenier D, Wolfe L. Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. SurgObesRelat Dis. 2007;3:134-40. [ Links ]
81. Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-54. [ Links ]
Baker IDI, Heart and Diabetes
Institute, Level 4, 99 Commercial Road, Melbourne, Victoria 3004, USA
Received on May/17/2011
Accepted on Jun/20/2011
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
*This article was first published in Diabetic Medicine. 2011, Volume 28, Issue 6; 628-642.